Rimonabant, a potent CB1 cannabinoid receptor antagonist, is a Gαi/o protein inhibitor.
Pooled analysis of three randomized, double‐blind, placebo controlled trials with rimonabant for smoking cessation
Tags: Acomplia®, anorectic, anti-obesity, cannabinoid receptor CB1 inverse agonist, SR141719, Zimulti®
BASi Method Number SAP.1086
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
